SAN FRANCISCO, Feb. 17, 2016 /PRNewswire/ -- iRhythm Technologies, Inc., a leading digital health care solutions company focused on the advancement of cardiac care, today announced a recent study that found that a non-trivial percentage of potentially high-risk cardiac arrhythmias were identified after the initial 48-hour window that is the typical prescribed wear period for Holter electrocardiographic (ECG) monitors. The study led by researchers from Kaiser Permanente Northern California, "Incidence and Timing of Potentially High-Risk Arrhythmias Detected Through Long Term Continuous Ambulatory Electrocardiographic Monitoring," was published today in BioMed Central Cardiovascular Disorders.
The study examined 128,401 episodes of monitoring between 2012-2013 using iRhythm's ZIO® Service where the average monitor wear time was nearly 10 days and more than one quarter were worn for almost 14 days. iRhythm's ZIO® Service, a non-invasive, leadless, cardiac monitor that can record and store up to 14 days of ECG data, was used to measure the occurrence and timing of potentially high-risk arrhythmias, including ventricular tachycardia, high grade heart block and clinically significant pauses in atrioventricular conduction.
"The research highlights that uncommon but potentially serious arrhythmias were detected with longer-term continuous ECG monitoring using this non-invasive approach," said Dr. Alan S. Go, Chief, Cardiovascular and Metabolic Conditions Research, at Kaiser Permanente. "Additional efforts are needed to determine if detecting these arrhythmias that may be missed using other monitoring strategies leads to better patient outcomes by earlier evaluation and management."
The study found that for episodes of sustained ventricular tachycardia, one third were observed more than 48 hours after monitoring started, while more than half of potentially serious bradyarrhythmias were identified after the initial 48 hours of Holter monitoring. Furthermore, there was an incrementally higher detection of potentially high-risk arrhythmias with longer continuous ambulatory ECG monitoring during the 14-day maximum monitoring period.
"This study supports the concept that targeted patients may benefit from solutions such as the ZIO Service, which analyzes beat-to-beat data over the course of up to 14 days, for more comprehensive identification of clinically important arrhythmias," said Judy Lenane, RN, MHA, executive vice president and chief clinical officer of iRhythm Technologies, Inc.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital healthcare company focused on cardiac arrhythmia detection. The company combines wearable biosensor devices with mobile and cloud-based technology to improve how heart arrhythmias are diagnosed and managed. iRhythm's digital health technology and diagnostic support services provide clear, actionable information for physicians, and are clinically proven to enhance clinical decision making and to lower healthcare costs. Its flagship solution, the ZIO Service, offers a proven approach to continuous ECG monitoring for up to 14 days. The ZIO Service enables physicians to diagnose arrhythmias earlier in the clinical pathway in order to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com. The ZIO Service has been used with over 400,000 patients at nearly 1,000 institutions across the U.S., making use of over 100 million hours of heartbeat data from continuous ECG recordings.
SOURCE iRhythm Technologies, Inc.